The present disclosure provides a preparation method of an artificial antibody. The preparation method includes the following steps: screening a target siRNA from a conserved gene or a microsatellite of a coronavirus, synthesizing a small hairpin RNA (shRNA) that has a loop by complementary sense and antisense strands of the siRNA, synthesizing an ACE2 capable of binding to a receptor-binding domain (RBD), and synthesizing the artificial antibody including an shRNA region and an ACE2 region by ligating the ACE2 to sense and antisense strands of the shRNA separately. The bivalent ACE2 is used for neutralization of the RBD and targeted delivery of the shRNA; the shRNA is ligated to the virus through the ACE2 and enters target cells with virus infection, thereby avoiding a side effect of non-specific delivery of the shRNA to uninfected cells, as well as resisting the variant strain and neutralizing the virus with the ACE2.

The present disclosure provides methods of treating a disease in a non-rodent mammal comprising administering to the cerebrospinal fluid (CSF) of the non-rodent mammal an rAAV2 particle containing a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV inverted terminal repeats in a manner effective to infect an ependymal cell in the non-rodent mammal, wherein the ependymal cell secretes the therapeutic protein so as to treat the disease.

The present invention provides a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Also, the present invention provides a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by said identifying method.

The present invention provides a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Also, the present invention provides a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by said identifying method.

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

The present disclosure concerns a recombinant yeast host cell exhibiting higher stability and, in some embodiments, higher fermentation performance. The recombinant yeast host cell stability has a limited ability to express an hydrolase during its propagation phase. In return, this limits the cleavage of a yeast cellular component during or after propagation which may be detrimental to the stability and/or fermentation performances. The recombinant yeast host cell expresses a heterologous hydrolase under the control of a heterologous promoter (for limiting the expression of the heterologous hydrolase during propagation and favoring the expression of the heterologous hydrolase during fermentation).

The present disclosure concerns a recombinant yeast host cell exhibiting higher stability and, in some embodiments, higher fermentation performance. The recombinant yeast host cell stability has a limited ability to express an hydrolase during its propagation phase. In return, this limits the cleavage of a yeast cellular component during or after propagation which may be detrimental to the stability and/or fermentation performances. The recombinant yeast host cell expresses a heterologous hydrolase under the control of a heterologous promoter (for limiting the expression of the heterologous hydrolase during propagation and favoring the expression of the heterologous hydrolase during fermentation).

The present invention relates to a novel thermophile-derived keratinase having keratin decomposition ability. Further, the present invention relates to a polynucleotide encoding the keratinase, a recombinant vector containing the same, host cells transformed by using the recombinant vector, and a method for preparing a keratinase including a step of culturing the host cells. Further, the present invention relates to a composition for decomposing keratin containing the enzyme; and a method for decomposing keratin by using the same. Further, the present invention relates to a keratin decomposed product decomposed by the enzyme.

The keratinase according to the present invention rapidly and effectively decomposes hardly-decomposable keratin, and thus it is expected that the keratinase can be used for the effective treatment and the high value-added resource recovery of agricultural and livestock waste, which causes environmental problems (for example, a novel material for enzyme cosmetics), and can be used in an innovative enzymatic bioconversion technique utilizing various decomposition enzyme groups.

The present invention relates to a novel thermophile-derived keratinase having keratin decomposition ability. Further, the present invention relates to a polynucleotide encoding the keratinase, a recombinant vector containing the same, host cells transformed by using the recombinant vector, and a method for preparing a keratinase including a step of culturing the host cells. Further, the present invention relates to a composition for decomposing keratin containing the enzyme; and a method for decomposing keratin by using the same. Further, the present invention relates to a keratin decomposed product decomposed by the enzyme.

The keratinase according to the present invention rapidly and effectively decomposes hardly-decomposable keratin, and thus it is expected that the keratinase can be used for the effective treatment and the high value-added resource recovery of agricultural and livestock waste, which causes environmental problems (for example, a novel material for enzyme cosmetics), and can be used in an innovative enzymatic bioconversion technique utilizing various decomposition enzyme groups.

The reformulation of RONOZYME® ProAct protease polypeptide to a more economical microgranulate, extrudate, high-shear granulate or spray drying formulation each provide good thermostability and suitability for use as an animal feed additive.